P61964 (WDR5_HUMAN) Homo sapiens (Human)

WD repeat-containing protein 5 UniProtKBInterProSTRINGInteractive Modelling

334 aa; Sequence (Fasta) ; 69 identical sequences

Available Structures

144 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
X-ray structure of WDR5 bound to the WDR5 win motif peptide
7bed
 Heteromer
10-334
1×SO4;
Assess
Modulating Protein-Protein Interactions with Visible Light Peptide Backbone Switches
6iam
 Heteromer
G2XKQ0; 		29-334
3×K; 2×NA;
Assess
WDR5 and Histone H3 Lysine 4 dimethyl complex at 2.1 angstrom
2cnx
 Heteromer
P68431; 		29-334
Assess
WDR5 in complex with influenza NS1 C-terminal tail
4o45
 Heteromer
P03495; 		30-334
17×UNX;
Assess
X-ray structure of WDR5-MLL3 Win motif peptide binary complex
4ery
 Heteromer
Q8NEZ4; 		31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL2
3uvk
 Heteromer
O14686; 		31-334
1×BTB; 1×SO4;
Assess
Crystal structure of the KANSL1-WDR5 complex.
4cy1
 Heteromer
Q7Z3B3; 		31-334
2×GOL;
Assess
X-ray structure of WDR5delta24 bound to the Kaposi's sarcoma herpesvirus LANA win motif peptide
7bcy
 Heteromer
Q9QR71; 		31-334
Assess
X-ray structure of WDR5-SETd1a Win motif peptide binary complex
4ewr
 Heteromer
O15047; 		31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL4
3uvm
 Heteromer
Q9UMN6; 		31-334
Assess
Crystal structure of WDR5 in complex with H3K4me3Q5ser peptide
7cfq
 Heteromer
P68431; 		31-334
1×GOL; 1×EDO; 1×SRO;
Assess
Crystal structure of WDR5 in complex with a H3Q5ser peptide
7cfp
 Heteromer
P68431; 		31-334
1×SRO;
Assess
Crystal structure of human WDR5 in complex with monomethyl H3R2 peptide
6oi3
 Heteromer
Q6NXT2; 		31-334
3×GOL; 1×SO4;
Assess
X-ray structure of WDR5-MLL1 Win motif peptide binary complex
4esg
 Heteromer
Q03164; 		31-334
Assess
Structure of WDR5 bound to MLL1 peptide
3eg6
 Heteromer
Q03164; 		31-334
3×SO4;
Assess
X-ray structure of WDR5-MLL4 Win motif peptide binary complex
4erz
 Heteromer
Q9UMN6; 		31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1A
3uvn
 Heteromer
O15047; 		31-334
Assess
X-ray structure of WDR5-SETd1b Win motif peptide binary complex
4es0
 Heteromer
Q9UPS6; 		31-334
Assess
Crystal structure of WDR5 in complex with MYC MbIIIb peptide
4y7r
 Heteromer
P01106; 		31-334
1×TRS; 1×EDO;
Assess
WDR5 in complex with unmodified H3K4 peptide
2h9m
 Heteromer
Q6P823; 		31-334
Assess
X-ray structure of WDR5-MLL2 Win motif peptide binary complex
4erq
 Heteromer
O14686; 		31-334
Assess
WDR5 in complex with trimethylated H3K4 peptide
2h9p
 Heteromer
Q6P823; 		31-334
Assess
Crystal structure of the KANSL1-WDR5-KANSL2 complex.
4cy2
 Heteromer
Q7Z3B3; Q9H9L4; 		31-334
Assess
WDR5 in complex with monomethylated H3K4 peptide
2h9n
 Heteromer
Q6P823; 		31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL3
3uvl
 Heteromer
Q8NEZ4; 		31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1B
3uvo
 Heteromer
Q9UPS6; 		31-334
Assess
WDR5 and unmodified Histone H3 complex at 2.25 angstrom
2co0
 Heteromer
P68431; 		31-334
Assess
Structural and biochemical insights into MLL1 core complex assembly and regulation.
3p4f
 Heteromer
Q03164; Q15291; 		31-334
Assess
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE RECRUITED TO NOVEL SITE
2xl2
 Heteromer
P61965; Q8BX09; 		31-334
2×GOL;
Assess
Quaternary Complex of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC Homer
7q2j
 Heteromer
P40337; Q15369; Q15370; 		30-333
1×8KH;
Assess
Crystal structure of WDR5-Mb(S4) monobody complex
6byn
 Heteromer
31-334
Assess
Crystal structure of Protac MS33 in complex with the WD repeat-containing protein 5 and pVHL:Elongi…
7jto
 Heteromer
P40337; Q15369; Q15370; 		32-334
4×SCN; 5×EDO; 1×VKA; 1×GOL; 1×NA;
Assess
Symmetric Dimethylation of H3 Arginine 2 is a Novel Histone Mark that Supports Euchromatin Maintena…
4a7j
 Heteromer
P68431; 		32-334
Assess
Crystal structure of Protac MS67 in complex with the WD repeat-containing protein 5 and pVHL:Elongi…
7jtp
 Heteromer
P40337; Q15369; Q15370; 		32-334
1×GOL; 1×X6M;
Assess
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE AND HISTONE H3 PEPTIDE
2xl3
 Heteromer
P61965; P68433; Q8BX09; 		32-334
2×GOL;
Assess
Crystal structure of WDR5 in complex with the WIN peptide of PDPK1
6wjq
 Heteromer
O15530; 		30-332
Assess
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla…
6w5i
 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; 		32-334
Assess
Cryo-EM structure of MLL1 core complex bound to the nucleosome
6pwv
 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9C005; Q9UBL3; 		32-334
2×SAH; 2×ZN;
Assess
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla…
6w5m
 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; 		32-334
Assess
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla…
6w5n
 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; 		32-334
Assess
Cryo-EM structure of MLL1 in complex with RbBP5 and WDR5 bound to the nucleosome
6pww
 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; 		32-334
1×SAH; 1×ZN;
Assess
Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode02
7mbn
 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; 		32-334
Assess
Complex between RbBP5-WDR5 and an H2B-ubiquitinated nucleosome
8du4
 Heteromer
P02281; P02302; P06897; P0CG47; P62799; Q15291; 		32-334
Assess
Complex between MLL1-WRAD and an H2B-ubiquitinated nucleosome
7ud5
 Heteromer
B4DIJ7; P02281; P06897; P0CG47; P62799; P84233; Q15291; Q9C005; Q9UBL3; 		32-334
1×SAH; 1×ZN;
Assess
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #1)
8bb3
 Heteromer
P40337; Q15369; Q15370; 		33-334
15×SCN; 13×EDO; 1×P6G; 1×Q3X;
Assess
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #2)
8bb2
 Heteromer
P40337; Q15369; Q15370; 		33-334
5×SCN; 1×Q3X; 7×EDO;
Assess
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with C3 linker
8bb4
 Heteromer
P40337; Q15369; Q15370; 		33-334
1×Q3R;
Assess
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with Aryl linker
8bb5
 Heteromer
P40337; Q15369; Q15370; 		33-333
10×SCN; 1×Q43; 4×EDO; 1×K;
Assess
Structural basis of WDR5-MLL interaction
3emh
 Heteromer
Q03164; 		33-332
2×SO4;
Assess
Cryo-EM structure of human MLL1-NCP complex, binding mode2
6kiz
 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; 		33-332
1×SAH; 1×ZN;
Assess
Cryo-EM structure of human MLL3-ubNCP complex (4.0 angstrom)
6kiw
 Heteromer
P02281; P06897; P62799; P62979; P84233; Q15291; Q8NEZ4; Q9UBL3; 		33-332
1×ZN;
Assess
Cryo-EM structure of human MLL1-NCP complex, binding mode1
6kix
 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; 		33-332
1×SAH; 1×ZN; 1×LYS; 1×GLN;
Assess
Cryo-EM structure of human MLL1-ubNCP complex (4.0 angstrom)
6kiv
 Heteromer
P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3; 		33-332
1×SAH; 1×ZN;
Assess
Cryo-EM structure of human MLL1-ubNCP complex (3.2 angstrom)
6kiu
 Heteromer
P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3; 		33-332
1×SAH; 1×ZN; 1×LYS; 1×GLN;
Assess
Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode01
7mbm
 Heteromer
P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; 		33-332
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…
6uoz
homo-2-mer31-334
2×QF1;
Assess
Characterization of Peptide Ligands Against WDR5 Isolated Using Phage Display Technique
7dno
homo-2-mer31-334
Assess
Structure of wdr5
2gnq
monomer11-334
1×CL;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…
6ujh
monomer22-334
1×QBS; 2×SO4;
Assess
Structure of the cryo-trapped WDR5:CS-VIP8 cocrystal after illumination at 405 nm and 180 K
7axq
monomer22-334
Assess
Structure of WDR5:CS-VIP8 cocrystal after illumination in situ
7axu
monomer22-334
Assess
Structural characterisation of WDR5:CS-VIP8 interaction in cis state 1
7axs
monomer22-334
Assess
Structure of WDR5:CS-VIP8 crystal after illumination at 405 nm and room temperature
7axx
monomer23-334
1×ALQ; 1×4FO; 1×EDN; 1×S7Z;
Assess
Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dih…
6ucs
monomer23-334
1×Q41;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…
6u6w
monomer24-334
1×Q0Y;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…
6u8b
monomer24-334
1×Q1M;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…
6u80
monomer24-334
1×Q1J;
Assess
Crystal structure of human WDR5 in complex with compound 9e
5eap
monomer24-334
1×5MO; 1×GOL; 1×CL; 5×EDO; 14×UNX;
Assess
WDR5delta23
2h9l
monomer24-334
2×SO4;
Assess
Crystal structure of human WD repeat domain 5 with compound MM-401
4gm9
monomer24-334
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity
6e1z
monomer28-334
1×HLP;
Assess
Crystal structure of human WD repeat domain 5 with compound MM-402
4gmb
monomer28-334
Assess
WD repeat-containing protein 5 complexed with 4-(7-((1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(triflu…
8e9f
monomer30-334
1×BEN; 1×UY9;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…
6ujl
monomer30-334
2×QBM;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…
6dai
monomer30-334
2×DMS; 2×G2V;
Assess
Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-me…
4ia9
monomer30-334
1×IA9; 2×EDO; 24×UNX;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…
6ujj
monomer30-334
1×QBP;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…
6das
monomer30-334
1×G2D;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…
6d9x
monomer30-334
1×NA; 1×FZM;
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex
2h6k
monomer30-334
Assess
WDR5 bound to 2-(3,5-dimethoxybenzyl)-7-((2-methyl-1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluor…
7u9y
monomer30-334
1×BEN; 1×M4U;
Assess
WDR5 in complex with a WIN site inhibitor
6dya
monomer30-334
1×HHM; 1×SO4; 2×DMS;
Assess
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…
2g9a
monomer29-333
Assess
WDR5 in complex with Myc site fragment inhibitor
6uhz
monomer31-334
1×Q8D;
Assess
WDR5 in complex with Myc site fragment inhibitor
6uhy
monomer31-334
1×Q8G;
Assess
Crystal structure of human WDR5 in complex with compound 19
7wvk
monomer31-334
1×6IQ; 4×GOL; 4×EDO;
Assess
Crystal structure of human WDR5 in complex with compound OICR-9429
4ql1
monomer31-334
1×35Q; 1×UNX;
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex
2h6n
monomer31-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…
6uj4
monomer31-334
1×Q8S;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…
6u5y
monomer31-334
1×Q0M;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…
6u8l
monomer31-334
1×Q1P; 1×Q1S;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…
6u8o
monomer31-334
1×Q1G;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…
6dak
monomer31-334
1×G1Y; 1×DMS;
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity
6e22
monomer31-334
1×HLS; 1×SO4;
Assess
WDR5 bound to inhibitor MM-589
5vfc
monomer31-334
1×9BA; 1×SO4; 7×EDO;
Assess
WDR5delta23 bound to (2-(3-phenylpropyl)-1H-imidazol-4-yl)methanol
6pg8
monomer31-334
1×OGY; 1×CL;
Assess
Crystal structure of human WDR5 in complex with monomethyl L-arginine
6oi1
monomer31-334
1×SO4; 2×GOL; 1×NMM;
Assess
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acetamide
6pg6
monomer31-334
1×SO4; 1×OH7; 1×CL;
Assess
Crystal structure of human WDR5 in complex with symmetric dimethyl-L-arginine
6oi2
monomer31-334
3×SO4; 3×GOL; 1×2MR;
Assess
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)benzamide
6pg9
monomer31-334
1×OH1;
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex
2h68
monomer31-334
Assess
Crystal structure of human WD repeat domain 5 with compound
3ur4
monomer31-334
1×0BW; 2×EDO; 4×CL; 2×SO4; 17×UNX;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…
6u5m
monomer31-334
1×Q0S;
Assess
Crystal structure of human WDR5 in complex with compound 9o
5eam
monomer31-334
1×5MN; 1×EDO; 11×UNX;
Assess
Crystal structure of WDR5, WD repeat domain 5 in complex with compound SGC-DS-MT-0345
4qqe
monomer31-334
1×37F; 1×CL; 3×EDO; 7×UNX;
Assess
Crystal structure of human WDR5 in complex with compound 9d
5ear
monomer31-334
1×5MQ; 9×EDO; 2×UNX;
Assess
Crystal structure of human WDR5 in complex with compound 9h
5eal
monomer31-334
1×5ML; 1×GOL; 1×CL; 8×EDO; 13×UNX;
Assess
Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-…
7uas
monomer31-334
1×MBU;
Assess
Crystal structure of human WD repeat domain 5 with compound
3smr
monomer31-334
1×NP7; 8×EDO; 7×UNX;
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex
2h6q
monomer31-334
Assess
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…
2g99
monomer30-333
Assess
WDR5 in complex with a WIN site inhibitor
6dy7
monomer31-334
1×HH7; 1×DMS; 1×SO4;
Assess
WDR5 in Complex with Dimethylated H3K4 Peptide
2o9k
monomer31-334
Assess
Crystal structure of human WDR5 in complex with L-arginine
6oi0
monomer31-334
1×ARG; 2×SO4; 4×GOL;
Assess
WDR5 in complex with MLL Win motif peptidomimetic
5sxm
monomer31-334
Assess
WDR5delta23 bound to (2-butyl-1H-imidazol-4-yl)methanol
6pg3
monomer31-334
1×OHJ;
Assess
Crystal structure of WDR5 mutant (S62A)
3mxx
monomer31-334
Assess
Crystal structure of WDR5 mutant (W330F)
3n0d
monomer31-334
Assess
Structural characterisation of WDR5:CS-VIP8 interaction in cis state 2
7axp
monomer30-333
Assess
Crystal structure of WDR5 mutant (W330Y)
3n0e
monomer31-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-102
4gm8
monomer31-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-101
4gm3
monomer31-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…
6e1y
monomer32-334
1×HLM;
Assess
Crystal of WDR5 (apo-form)
2h14
monomer32-334
Assess
WDR5delta32 bound to peptidomimetic
6pgd
monomer32-334
1×OK4; 3×SO4;
Assess
WDR5delta32 bound to N-(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acrylamide
6pgf
monomer32-334
1×OJP; 3×SO4;
Assess
Crystal structure of WDR5/histone H3 complex
2h13
monomer32-334
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…
6uik
monomer32-334
1×Q8M;
Assess
WDR5delta32 bound to (2-methyl-1H-imidazol-4-yl)methanol
6pg4
monomer32-334
1×OHG; 3×SO4;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…
6uif
monomer32-334
1×Q8P;
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity
6e23
monomer32-334
1×HLJ;
Assess
Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3 based peptide mimetic
3psl
monomer32-334
Assess
WDR5delta32 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)-2-phenylacetamide
6pgb
monomer32-334
1×OJG; 3×SO4;
Assess
WDR5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1H-imidazol-2-yl)propanoate
6pge
monomer32-334
1×OJM; 2×SO4; 1×EDO;
Assess
WDR5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate
6pgc
monomer32-334
2×SO4; 1×OJJ;
Assess
Crystal structure of human WDR5
6ofz
monomer32-334
Assess
WDR5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate
6pg5
monomer32-334
1×OHV; 3×SO4;
Assess
WD repeat-containing protein 5 complexed with N-[(3,5-dimethoxyphenyl)methyl]-4'-fluoro-5-{[(2E)-2-…
6ufx
monomer32-334
1×Q6S;
Assess
Crystal structure of human WDR5 in complex with compound WM662
8f1g
monomer31-333
1×X8N; 4×GOL; 1×SO4; 1×PGE;
Assess
WDR5delta32 bound to methyl (4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate
6pga
monomer32-334
1×OGM; 1×SO4;
Assess
WDR5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1H-imidazol-4-yl)methanol
6pg7
monomer32-334
1×OH4; 1×PEG;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…
6dar
monomer31-332
1×G2J; 2×SO4; 2×DMS;
Assess
Modulation of MLL1 Methyltransferase Activity
5m23
monomer33-332
1×7DC;
Assess
Modulation of MLL1 Methyltransferase Activity
5m25
monomer33-332
1×7DU;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
2gnq.1.Amonomer0.9111-334
100.00
Assess